Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash Flows from Operating Activities:
Net income	$ 69,117	$ 78,778
Operating distributions received from unconsolidated joint ventures	1,475	1,805
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	91,376	84,100
Amortization of deferred financing costs	1,931	2,056
Settlement of forward starting interest rate swaps	672	0
Other amortization	34,384	38,895
Impairment loss on real estate assets	6,402	0
Stock compensation expense	1,489	1,492
Equity in income of unconsolidated joint ventures	(604)	(740)
Gain on sale of real estate assets, net	(16,258)	(27,583)
Loss on consolidation	(898)	0
Changes in assets and liabilities:
Increase in tenant receivables, net	(24,257)	(15,358)
Increase in restricted cash and escrows	(51)	(13,813)
Increase in prepaid expenses and other assets	(4,539)	(3,335)
Increase/(decrease) in accounts payable and accrued expenses	1,291	(483)
Increase/(decrease) in deferred income	5,022	(3,211)
Net cash provided by operating activities	168,348	142,603
Cash Flows from Investing Activities:
Acquisition of real estate assets and related intangibles	(250,127)	(2,500)
Capitalized expenditures, net of accruals	(112,486)	(71,936)
Acquisition of unconsolidated joint ventures, net of cash assumed	(14,242)	0
Net sales proceeds from wholly-owned properties	49,326	74,845
Investments in unconsolidated joint ventures	(793)	0
Deferred lease costs paid	(28,349)	(39,319)
Net cash used in investing activities	(356,671)	(38,910)
Cash Flows from Financing Activities:
Deferred financing costs paid	(3,447)	(2,991)
Proceeds from debt	832,603	365,000
Repayments of debt	(426,000)	(401,500)
Costs of issuance of common stock	(91)	(229)
Repurchases of common stock as part of announced plan	(111,625)	(80,130)
Dividends paid and discount on dividend reinvestments	(100,102)	(102,770)
Net cash provided by/(used in) financing activities	191,338	(222,620)
Net increase/(decrease) in cash and cash equivalents	3,015	(118,927)
Cash and cash equivalents, beginning of period	12,957	139,690
Cash and cash equivalents, end of period	15,972	20,763
Supplemental Disclosures of Significant Noncash Investing and Financing Activities:
Change in accrued share repurchases as part of an announced plan	726	0
Accrued capital expenditures and deferred lease costs	38,837	11,177
Accrued deferred financing costs	$ 0	$ 110